“Cramer Says IMAX is Fun to Watch—Don’t Miss Out!”

Company Overview

IMAX Corporation (NYSE: IMAX) is an entertainment technology company that provides large-format cinema systems and services, rather than operating conventional movie theater chains (www.cnbc.com). Its model involves selling or leasing IMAX projection systems to theater operators (like AMC and Regal) and earning ongoing revenue from maintenance services and box-office sharing (www.cnbc.com). This asset-light approach has positioned IMAX to capitalize on premium movie-going experiences without the heavy fixed costs that burden typical exhibitors. The company’s global network is significant – as of the end of 2023, IMAX had 807 systems in Greater China alone (its largest market) and a total backlog of 206 new systems there, accounting for ~46% of its global backlog (www.sec.gov).

Recent performance underscores IMAX’s momentum: the company reported record global IMAX box-office grosses of $1.28 billion in 2025, up 40% from the prior year and 13% above its pre-pandemic record (2019) (www.screendaily.com). In North America, 2025 was IMAX’s best year ever ($449 million gross), and international markets were equally robust with $427 million ex-China and $407 million in China (www.screendaily.com). IMAX’s content slate has expanded to more local-language and international films, contributing to a record $405 million in non-Hollywood box office for 2025 (up 65% vs 2023) (www.screendaily.com). In the words of CEO Richard Gelfond, “2025 was truly a transformational year,” and the company is forecasting an even bigger $1.4 billion global IMAX box office in 2026 given a strong upcoming film lineup (www.screendaily.com).

Industry commentators note IMAX is increasingly defining what a blockbuster success looks like. CNBC’s Jim Cramer has highlighted IMAX as perhaps “the best way to invest in the movie industry”, given its unique niche and strong sales momentum (www.cnbc.com) (www.cnbc.com). Unlike studios and traditional theaters that have struggled post-pandemic, IMAX benefits from being the premium format of choice – theaters willingly invest in IMAX to charge higher ticket prices, and audiences seek out the larger-than-life experience (www.cnbc.com) (www.cnbc.com). Cramer emphasized how IMAX-driven showings can boost ticket sales even when overall theater attendance is under pressure (www.cnbc.com). He even joked from personal experience that while watching movies on a big screen at home is nice, “the only thing that’s more fun is IMAX” – he enjoys going to an IMAX theater where he can get a burger, a beer (even a tequila), and have a better time than in his living room (www.insidermonkey.com). This customer appeal, combined with IMAX’s global reach and technology, underpins the company’s strong post-Covid recovery. Below, we dive into IMAX’s fundamentals – dividend policy, leverage, valuation, and key risks – to see if investors should indeed “not miss out” on this name.

URGENT: Get “Trump\’s Secret Fund” — Learn How to Collect Royalty Checks

Limited report reveals the #1 American oil & gas royalty play that can start paying monthly — with just $50.

Mobile-friendly
Start w/ $50

Yes — Send My Report
Fast download • Instant access • Seats limited

Dividend Policy and Shareholder Returns

IMAX does not pay a dividend on its common stock and has no current plans to initiate regular dividends (www.sec.gov). The company has instead prioritized reinvesting in growth and returning capital to shareholders via stock buybacks. In fact, IMAX’s debt covenants explicitly restrict it from paying dividends unless certain conditions are met (www.sec.gov), which effectively locks in the no-dividend policy for now. Consequently, IMAX’s dividend yield is 0%, and investors seeking income won’t find it here.

Instead of dividends, IMAX has aggressively repurchased its own shares in recent years. The Board of Directors first authorized a buyback program in 2017 and expanded it over time to a total authorization of $400 million, recently extending the program through June 30, 2026 (www.sec.gov). As of the end of 2023, $167 million of this authorization was still available for future buybacks (www.sec.gov). IMAX indeed made use of this program: for example, in the fourth quarter of 2023 alone the company repurchased about 1.46 million shares at an average price of $16.55, spending approximately $24.2 million (www.sec.gov). (For context, that quarterly repurchase retired roughly 3% of the float, as IMAX has ~54 million shares outstanding.) In the full-year 2023, IMAX spent $26.8 million on share repurchases, following an even larger $80.1 million buyback in 2022 when shares were lower (www.sec.gov) (www.sec.gov). These buybacks reflect management’s confidence in the company’s prospects and have been accretive to remaining shareholders.

It’s worth noting that IMAX’s free cash flow has rebounded strongly post-pandemic, supporting these capital returns. In 2023, the company generated $58.6 million in cash from operations, up from just $17 million in 2022, while capital expenditures were modest at around $6.5 million (www.sec.gov). This indicates robust free cash flow conversion, which IMAX has largely allocated to share repurchases (and minor strategic investments) rather than dividends. Investors should expect this policy to continue in the near term – management will likely keep focusing on growth initiatives (like expanding the IMAX network and technology) and opportunistic buybacks while the stock is, in their view, undervalued. Any potential future dividend would depend on sustained high cash flows, lower leverage, and relaxed lender restrictions, but for now IMAX remains a non-dividend growth stock (www.sec.gov).

Leverage, Debt Maturities & Coverage

IMAX carries a moderate debt load and has a healthy balance sheet with manageable leverage. The company’s primary debt is a $230 million issue of 0.50% Convertible Senior Notes due 2026 (www.sec.gov). These notes bear a very low interest rate (0.5% coupon) and mature on April 1, 2026 (www.sec.gov). Importantly, they are convertible to stock at an initial conversion price of about $28.75 per share (34.7766 shares per $1,000 note) (www.sec.gov). With IMAX’s stock trading in the mid-$30s recently, these notes are in the money, meaning noteholders may choose to convert to equity. Under the indenture, IMAX can settle conversions partly or entirely in cash, but either way by 2026 it must address this $230 million obligation (www.sec.gov) (www.sec.gov). If the share price remains above the conversion threshold, a likely scenario is that IMAX will pay the $230 million principal (cash) and issue some shares for the conversion value in excess of principal. The good news: IMAX’s liquidity resources should make this feasible (see below), and conversion at $28.75 would not be overly dilutive given the stock’s appreciation. However, if the stock were to fall well below $28.75 by 2026, the company might have to refinance or repay the notes fully in cash – a contingency to keep in mind.

Aside from the convertible notes, IMAX maintains a revolving credit facility to support general liquidity. In March 2022 the company amended and extended its secured credit agreement with Wells Fargo, pushing the maturity out to March 25, 2027 (www.sec.gov). This revolver provides up to $300 million in borrowing capacity (with an option to expand to $440 million under certain conditions) (www.sec.gov). As of December 31, 2023, IMAX had only $24 million drawn on this facility (www.sec.gov), leaving a substantial $276 million of unused credit available (www.sec.gov). The drawn portion currently bears interest at SOFR + 1.0–1.75%; with rising rates, IMAX paid about 6.8% effective interest on the revolver in 2023 (www.sec.gov). The credit agreement includes a financial covenant capping secured net leverage at 3.25× EBITDA – a threshold IMAX comfortably met with a net leverage of essentially 0.0× as of 2023 year-end (www.sec.gov). In practice, IMAX’s solid cash position (around $140 million of cash on hand) and minimal net debt mean it has significant borrowing headroom and flexibility.

IMAX’s total debt at 2023 year-end was roughly $257 million (including the convertible notes at accounting value and minor loans) (www.sec.gov). This figure is modest relative to the company’s equity base (debt-to-equity ~0.74) and cash flow generation. Interest coverage is very healthy – in 2023 IMAX incurred about $6.8 million in interest expense (www.sec.gov), while earning $46 million in pre-tax income (www.sec.gov). That’s roughly 7× coverage of interest by earnings, and coverage would be even higher using EBITDA. Even if interest rates rise or IMAX utilizes more of its revolver, the current interest obligations are easily serviced by operating cash flow. Furthermore, a portion of that interest expense is the non-cash amortization of the convertible notes’ discount (since the coupon is only 0.5%) (www.sec.gov), so cash interest paid is lower. In short, leverage does not pose a significant risk at present – IMAX has low net debt and ample liquidity to fund operations, growth, and the upcoming 2026 debt maturity.

The only notable debt aside from those mentioned is a small $3.2 million interest-free loan from a Canadian government agency (FedDev Ontario) related to an acquired subsidiary; this will be repaid in monthly installments over 36 months starting 2024 (www.sec.gov) (www.sec.gov). This obligation is minor and carries 0% interest, so it’s more of a formality on the balance sheet. Overall, IMAX’s debt maturity profile is very manageable: no major maturities until 2026 (the convertible notes), and then the credit facility in 2027. The company appears well-prepared to handle these – it could potentially use its revolver or cash on hand to retire the 2026 notes if needed, or refinance on favorable terms given its improving EBITDA and the strong brand/franchise it commands in the industry.

Valuation and Growth Outlook

IMAX’s stock has rallied strongly over the past year, reflecting its earnings recovery and growth prospects. Shares are up about 65% year-over-year (as of late February 2026) and roughly 15% year-to-date (www.insidermonkey.com), significantly outperforming the broader market. This performance has brought IMAX to a market capitalization near $2 billion and a forward P/E of around 22× earnings (finviz.com). In other words, investors are paying ~22 times the anticipated next-year profit for IMAX – a valuation that is not cheap in absolute terms, but arguably reasonable given the company’s double-digit revenue growth and expanding margins. IMAX’s PEG ratio (price/earnings-to-growth) is below 1, suggesting the stock’s price is in line with or lagging its growth rate (finviz.com). On a cash flow basis, IMAX trades at ~20× trailing free cash flow (i.e. a 5% FCF yield) (finviz.com), which again reflects expectations of rising cash generation in coming years. Meanwhile, the enterprise value to EBITDA multiple is roughly 15× (TTM) (finviz.com), which is in line with other asset-light, high-margin media/tech firms and a premium to traditional theater chains (which often trade at lower multiples due to debt burdens and flat growth).

Wall Street analysts remain bullish on IMAX. In the wake of strong Q4 2025 results (35% YoY revenue growth in Q4, and 16% growth for the full year) (www.insidermonkey.com), JPMorgan reiterated its Overweight rating and raised its price target to $48 (from $47) (www.insidermonkey.com). Similarly, Benchmark Company boosted its target to $44 and maintained a Buy rating (www.insidermonkey.com). These targets imply upside of ~20–30% from the mid-$30s share price in early 2026. The analysts cited IMAX’s market share gains in global box office and its expanding international footprint as key drivers for future earnings (www.insidermonkey.com). IMAX’s outperformance during 2023–2025 has demonstrated its ability to “break out and deliver at a higher level,” as CEO Gelfond put it (finviz.com). The company not only beat earnings expectations in recent quarters, but also signed a surge of new theater agreements – over 100 new or upgraded IMAX system signings in the first part of 2025 alone, nearly matching all of 2024’s 130 signings (www.cnbc.com). This points to accelerating adoption of IMAX technology by exhibitors worldwide, which should fuel future high-margin revenue (through system sales and recurring royalties).

Comparatively, IMAX’s valuation appears more demanding than traditional exhibitors like Cinemark or AMC, which have lower P/E ratios – but those peers are burdened with heavy debt and slow growth prospects. IMAX’s premium reflects its unique position and higher growth. For instance, Wedbush Securities recently added IMAX to its “best ideas” list, arguing that IMAX is well-positioned to capitalize on a strong film slate and a box-office rebound in China (seekingalpha.com). The stock also has a notable short interest (~14% of the float is sold short) (finviz.com). This suggests that some investors doubt the sustainability of the rally or worry the valuation has run ahead of fundamentals. A high short float can sometimes fuel additional upside if positive news forces shorts to cover, but it also indicates underlying skepticism. It’s possible that those short sellers anticipate a weaker 2026 box office than IMAX projects, or are simply hedging bets in a volatile sector.

Overall, IMAX’s current valuation prices in continued growth, but not necessarily perfection. The mid-20s earnings multiple and bullish price targets imply that investors expect the company’s strong box office trend to continue and even improve. If IMAX can hit its $1.4 billion global box office goal in 2026 and convert that into high-teens revenue growth (with operating leverage), earnings could rise sharply – justifying the current stock price or higher. Conversely, if the film slate underwhelms or if macro factors slow consumer spending on entertainment, IMAX’s growth could disappoint, leaving the stock looking expensive. Thus, while momentum is in IMAX’s favor, the execution in the next 12–18 months will be key to supporting its valuation.

Key Risks and Challenges

Every investment has risks, and IMAX is no exception. Here are some of the notable risk factors and challenges facing the company:

– Content Pipeline & Box Office Volatility: IMAX’s fortunes are tied to the success of blockbuster films and an active release slate. Fewer tentpole movie releases in a given period can mean lower IMAX box office revenue. This was evident during the pandemic and even in 2023 when Hollywood strikes and scheduling shifts delayed some films. If studios produce fewer big-screen spectacles – or if more films underperform – IMAX’s revenue growth could stall. The company’s record 2025 results were fueled by major titles like Avatar: Fire and Ash, Mission: Impossible – The Final Reckoning, and even local hits (Ne Zha 2 in China, etc.) (www.screendaily.com). A lighter lineup in any year (due to production delays, franchise fatigue, or competition from streaming content) poses a revenue concentration risk for IMAX.

– Streaming and At-Home Entertainment: The proliferation of streaming services and high-quality home theater setups remains a secular challenge for the theatrical industry. While IMAX offers a premium experience that is hard to replicate at home (as Cramer quipped, even a 90-inch TV and couch can’t match an IMAX outing (www.insidermonkey.com)), there’s a risk that consumer habits could continue shifting toward on-demand home viewing. If studios shorten or eliminate theatrical windows for major films – releasing them to streaming earlier – it could reduce the exclusive draw of seeing a film in IMAX. So far, post-pandemic trends show audiences still turn out for big event movies, especially in IMAX, but the long-term tug-of-war with streaming is something to monitor.

– Dependence on China & Geopolitics: IMAX has a significant exposure to Greater China, which accounted for roughly 25% of its total revenue in 2023 (www.sec.gov). China is IMAX’s largest market by screen count (800+ theaters) and contributed $407 million of IMAX’s 2025 global box office (www.screendaily.com). This reliance introduces risks including currency fluctuations (Chinese yuan), local economic cycles (a slowdown in Chinese consumer spending could hurt movie attendance), and regulatory or political issues. For example, Chinese regulators control import quotas of Hollywood films – any tensions in U.S.-China relations could impact how many big U.S. blockbusters get released on IMAX screens in China. Additionally, pandemic-related cinema closures hit China hard in 2022; any recurrence of widespread restrictions (due to health or other reasons) would directly affect IMAX’s business (www.sec.gov). Simply put, IMAX’s China exposure is both an opportunity and a risk, requiring careful watch.

– Technological and Competitive Risk: IMAX’s brand is strong, but it does face competition in the “premium large format” (PLF) cinema space. Theater chains have developed their own large-screen concepts (like Dolby Cinema, XD, etc.), and new technologies (such as advanced LED video walls or enhanced sound systems) could lessen IMAX’s technical edge. IMAX must continue to innovate – e.g. its laser projection systems, new IMAX film cameras for directors, and perhaps ventures into VR or other immersive tech – to stay ahead. If a disruptive display technology emerged that significantly improved the at-home or standard theater experience, IMAX could feel pressure. However, IMAX has decades of know-how in image/audio engineering and a deep content pipeline (studios specifically format films for IMAX), which provides a moat. The risk is more that theaters may opt for alternative upgrades if IMAX’s licensing fees are perceived as too high, or if a competitor offers a compelling PLF solution. So far, IMAX remains the gold standard, but tech disruption is always a background risk.

– Macroeconomic Factors: Going to the movies is a discretionary spend. Economic slowdowns or recessions could dent consumer confidence and disposable income, leading to weaker theater attendance. IMAX, being a premium offering (often a few dollars more per ticket), could be disproportionately affected if budget-conscious consumers cut back. Additionally, inflation in costs (energy, real estate, wages) can affect theater operators’ willingness to invest in new IMAX systems. IMAX does have a degree of insulation – its revenue comes from long-term theater deals and global markets – but a broad global recession could slow its system installations and revenue growth. Rising interest rates have already modestly increased IMAX’s cost of capital (e.g. higher interest on the revolver) (www.sec.gov), and if the company needed to refinance debt in a high-rate environment, interest costs could tick up (though its overall debt is low).

– Currency and Foreign Operations: Over 30% of IMAX’s revenues are generated outside the U.S., and a substantial portion in emerging markets. Currency fluctuations (e.g. a stronger U.S. dollar) can reduce reported revenues and profits. Moreover, operating in many countries introduces compliance and repatriation risks. For instance, IMAX’s operations in China involve partnerships (IMAX China is a Hong Kong-listed subsidiary) and exposure to Chinese regulations and capital controls. Unforeseen events – from China’s strict COVID policies in the past to changing foreign investment rules – can impact IMAX. The company being Canadian-incorporated also means U.S. investors operate under a slightly different legal regime, though that’s more of a technicality (it’s listed on NYSE). Investors should be aware that international risk factors (from exchange rates to local regulations) are part of owning IMAX (www.sec.gov).

– Convertible Debt and Dilution: While IMAX’s 0.5% convertible notes provided cheap financing, the April 2026 maturity presents a potential cash outlay of $230 million if noteholders don’t convert to equity. IMAX’s intent is likely to satisfy the principal in cash (as indicated by its “if-converted” accounting) (www.sec.gov) (www.sec.gov). This means the company might need to use a significant chunk of its cash or draw on the credit line in 2026. If business conditions are weak at that time, refinancing $230 million could be challenging or expensive. Conversely, if noteholders do convert, IMAX will issue new shares (for the conversion value above par) – this could cause dilution. At the $28.75 conversion price, up to ~8 million shares (max ~15% dilution) might be issued if fully converted, though IMAX can mitigate this via cash settlement or the capped call transactions it entered (which offset dilution above certain prices) (www.sec.gov). In any case, the handling of this debt in 2026 is a financial event to watch, and it could slightly impact EPS depending on the approach.

In summary, IMAX’s risks range from industry-wide challenges (supply of blockbuster films, streaming competition) to company-specific events (the convertible maturity, heavy China exposure). Investors should weigh these alongside the bullish thesis. The fact that short interest is relatively high (14% of float) (finviz.com) suggests some sophisticated investors are indeed betting on these risk factors causing a hiccup for IMAX.

Red Flags and Open Questions

Beyond the general risks above, a few red flags and open questions remain for IMAX that prospective investors may want to dig into:

– Failed IMAX China Buyout: In 2023, IMAX Corp attempted to acquire the remaining ~30% of its subsidiary IMAX China (a Hong Kong-listed unit) that it didn’t already own. The proposal received a “vast majority” of votes in favor but ultimately failed to meet the stringent 90% approval threshold of disinterested shareholders required by Hong Kong law (www.sec.gov). As a result, the buyout did not proceed and the $130 million funding set aside (via a bank letter of credit) was released (www.sec.gov). The open question is: what now? IMAX still owns about 70% of IMAX China and consolidates its results, but there are minority investors and separate management considerations. Will IMAX try again with a sweeter offer to take it private? Or has that ship sailed? The failure could be seen as a red flag that management spent time and resources on a deal that didn’t close. On the other hand, not completing the buyout preserves IMAX’s cash—perhaps prudent given other opportunities. Investors will want to watch for management’s next steps regarding IMAX China, as it’s a key asset. If no second bid comes, one might question if there’s any disconnect between IMAX and its IMAX China minorities that could affect strategy in that market.

– Corporate Structure and Governance: IMAX Corporation is incorporated in Canada and also has a complex structure with significant operations in China (including the partially public IMAX China subsidiary). While this hasn’t caused issues per se, it means shareholder rights and disclosures might differ slightly from a typical U.S.-domiciled firm. The company notes that because it’s Canadian, it may be difficult for U.S. investors to enforce certain legal claims (www.sec.gov). There’s no evidence of governance problems – in fact, management (led by CEO Rich Gelfond) has been steady for years – but investors have to be comfortable with the nuanced structure. Additionally, IMAX’s dual reporting (U.S. GAAP for SEC filings, and possibly some IFRS/local reporting) could make analysis complex. This isn’t a glaring red flag, but an area to keep in mind, especially if any future cross-border regulatory issues arise.

– Non-Recurring Items and Adjustments: Like many companies, IMAX reports “adjusted” metrics (e.g., Adjusted EBITDA) that back out certain costs. For instance, it incurs expenses for developing new technologies and write-downs of film assets. While so far there’s nothing alarming in their adjustments, investors should ensure that IMAX’s adjusted profits aren’t glossing over any chronic expense. One example: the amortization of film remastering costs and the expense of new camera development – these are real costs of doing business in IMAX’s model. If IMAX were to aggressively capitalize and amortize costs to boost short-term earnings, that would be a red flag. So far, though, the company’s operating margin of ~20% (finviz.com) and cash flow generation are strong, indicating quality of earnings. This point is simply an encouragement to keep an eye on one-time items (like any large impairment of theater equipment or goodwill, which can happen if a market underperforms).

– Reliance on Key Partners and Directors: IMAX’s largest single customer is Wanda Film (a huge Chinese theater chain), which alone represented about 10% of IMAX’s 2023 revenues (www.sec.gov). Wanda also accounts for 21% of IMAX’s commercial theater network (www.sec.gov). This relationship is vital – any financial strain at Wanda or renegotiation of terms could impact IMAX. It’s not a red flag per se (Wanda has been a strong partner), but a concentration to watch. Additionally, IMAX’s insider ownership is notable – insiders (including directors) own ~19% of the stock (finviz.com), and institutions about 93% of the float (finviz.com). Having a high insider stake often aligns management with shareholders, but it could also mean lower float and more volatility. No specific governance red flags are visible (the Board has independent members, etc.), but with any company where the CEO has a long tenure and strong influence, investors should monitor that capital allocation decisions (like the IMAX China bid, large buybacks, etc.) are made in shareholders’ best interests.

– What’s Next for Growth? A more open-ended question: beyond expanding the theater network and riding the film slate, how else can IMAX grow? The company made a small acquisition of SSIMWAVE (a video streaming optimization firm) in 2022 – hinting at interest in the streaming/video tech space. IMAX also licenses the “IMAX Enhanced” brand for home entertainment and has forayed into virtual reality arcades in the past. None of these are major contributors yet. So, an open question is whether IMAX can diversify its revenue streams (for example, more content production, live events broadcast in IMAX, or home-integrated tech) or if it remains essentially a one-trick (albeit a very good trick) pony centered on premium theatrical experiences. The answer will shape its long-term growth trajectory. If the core theater business eventually matures, having new growth vectors will be important. Investors will be looking for commentary from management on any such adjacent opportunities (and assessing the risk that they might pursue something far afield or capital intensive).

In reviewing IMAX, none of these “red flags” appear dire – rather, they are points to keep an eye on. The company’s fundamentals are currently strong, but prudent investors will continuously evaluate these open questions as the IMAX story unfolds.

Conclusion

IMAX Corporation has emerged from the pandemic era in a position of strength – revitalized box office revenues, global expansion, and a premium brand that resonates with moviegoers and theaters alike. Jim Cramer’s enthusiasm (“IMAX has tremendous momentum… IMAX seems like your best bet [in movies]” (www.cnbc.com) (www.cnbc.com)) encapsulates the bullish sentiment around the stock. The company offers a compelling growth narrative in an otherwise challenged industry: whereas traditional theaters and studios grapple with streaming disruption, IMAX thrives by enhancing the theater experience in a way that even streaming giants can’t easily replicate.

From a financial perspective, IMAX exhibits a solid balance sheet (minimal net debt and plenty of liquidity), rising revenues and cash flows, and a shareholder-friendly capital return approach (via buybacks). Its valuation – mid-30s stock pricing in ~22× forward earnings – reflects optimism but still leaves room for upside if IMAX delivers on earnings growth in 2026 and beyond. Analysts’ targets in the mid-to-high $40s suggest confidence that it can do so (www.insidermonkey.com). The absence of a dividend is made up for by the potential for capital gains and continued repurchases supporting the stock.

That said, investors shouldn’t overlook the risks. IMAX’s success hinges on robust content and continued consumer appetite for premium theatrical releases. Any stumble in the blockbuster pipeline or a shift in viewing habits could impact results. The 2026 convertible debt event and heavy exposure to China are additional factors to monitor, though they appear manageable at this stage.

In summary, IMAX is a unique equity story – part tech, part media, part leisure, with a globally recognized brand. It offers a play on the recovery and evolution of movie-going. As Cramer’s comments imply, IMAX can be “fun to watch” not just as a movie format but as an investment. For those bullish on the communal cinematic experience surviving and thriving alongside streaming, IMAX provides a picks-and-shovels way to invest in that thesis. There are clear growth drivers on the horizon (more IMAX screens, bigger film slates, emerging market expansion) but also challenges that need navigating. Investors should weigh these factors, but certainly don’t miss out on doing the homework – IMAX merits a close look as a differentiated growth play in the entertainment sector. (www.cnbc.com) (www.cnbc.com)

For informational purposes only; not investment advice.